Clinical Trial Detail

NCT ID NCT02065765
Title International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Recruitment No longer available
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

stomach carcinoma

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Ramucirumab

Age Groups: adult

No variant requirements are available.